Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of a Fourth Hexavalent Vaccine Dose Post-HSCT
NCT03402776Phase 3Unknown
- Sponsor
- CHU Grenoble Alpes
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Hexavalent Vaccine in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by CHU Grenoble Alpes. Status: unknown.
02
Drugs
Hexavalent Vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT03402776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402776.